Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

San Francisco, USA
953 Indiana Street
San Francisco, CA, 94107
USA

People

President and CEO

Funding

VENTURE FUNDING
Series A, 10/2013
Polaris Partners
OrbiMed Advisors

Tags

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

Recent Milestones

Videos

Screenshots

Alector screenshot
Above: Homepage
Uploaded: 10/31/13

Sources

  1. Alector LLC Secures Series A Financing to Find Cure for Alzheimer’s and Related Diseases (businesswire.com) [edit]
Edit This Page
Last Edited 12/24/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy